Jefferies analyst Gena Wang downgraded Sarepta Therapeutics to Underperform saying she continues to see a low probability of approval for eteplirsen by the May 26 FDA action date. While Dr. Woodcock's sympathy to Duchenne muscular dystrophy patients fueled some speculation on potential approval, the FDA officials emphasized that the agency is a science-based organization, Wang tells investors in a research note. She believes the "current weak evidence" based on the FDA's analysis could not support the drug's effect. Wang keeps a $7 price target for shares of Sarepta. The stock closed yesterday up 19% to $13.80 after TheStreet's Adam Feuerstein wrote about the FDA leaving the door open for approval.